Tokyo, Japan, Mar 12, 2008 - (JCN Newswire) - M’s Science Corporation and Eisai Co., Ltd. (TSE: 4523) announced today that the companies entered into an option agreement for SA4503, a novel sigma agonist which is being developed by M’s Science in Europe for the treatment of depression and post-stroke therapy.
